{"pmid":32319207,"title":"COVID-19 and viral hepatitis elimination programs: Are we stepping backward?","text":["COVID-19 and viral hepatitis elimination programs: Are we stepping backward?","As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030. This means that the number of newly infected persons and related mortality should be decreased by 90% and 65%, respectively. The elimination programs focus on different parts such as testing, treatment, immunization against hepatitis B virus (HBV), preventing mother to child transmission, blood safety, and harm reduction. Now, COVID-19 is spreading fast throughout the world and more than one million people have been affected by this virus so far. While all attentions are now on providing effective medicines and vaccines for COVID-19, we should not forget other viruses and diseases.","Liver Int","Karimi-Sari, Hamidreza","Rezaee-Zavareh, Mohammad Saeid","32319207"],"abstract":["As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030. This means that the number of newly infected persons and related mortality should be decreased by 90% and 65%, respectively. The elimination programs focus on different parts such as testing, treatment, immunization against hepatitis B virus (HBV), preventing mother to child transmission, blood safety, and harm reduction. Now, COVID-19 is spreading fast throughout the world and more than one million people have been affected by this virus so far. While all attentions are now on providing effective medicines and vaccines for COVID-19, we should not forget other viruses and diseases."],"journal":"Liver Int","authors":["Karimi-Sari, Hamidreza","Rezaee-Zavareh, Mohammad Saeid"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319207","week":"202017|Apr 20 - Apr 26","doi":"10.1111/liv.14486","keywords":["covid-19","hepatitis b","hepatitis c","viral hepatitis","elimination"],"source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664815087844589569,"score":8.518259,"similar":[{"pmid":32185921,"title":"[Challenges and countermeasures on Chinese malaria elimination programme during the coronavirus disease 2019 (COVID-19) outbreak].","text":["[Challenges and countermeasures on Chinese malaria elimination programme during the coronavirus disease 2019 (COVID-19) outbreak].","Since the end of 2019, the coronavirus disease 2019 (COVID-19) has been extensively epidemic in China, which not only seriously threatens the safety and health of Chinese people, but also challenges the management of other infectious diseases. Currently, there are still approximately three thousand malaria cases imported into China every year. If the diagnosis and treatment of malaria cases as well as the investigation and response of the epidemic foci are not carried out timely, it may endanger patients'lives and cause the possible of secondary transmission, which threatens the achievements of malaria elimination in China. Due to the extensive spread and high transmission ability of the COVID-19, there is a possibility of virus infections among malaria cases during the medical care-seeking behaviors and among healthcare professionals during clinical diagnosis and treatment, sample collection and testing and epidemiological surveys. This paper analyzes the challenges of the COVID-19 for Chinese malaria elimination programme, and proposes the countermeasures in response to the COVID-19 outbreak, so as to provide the reference for healthcare professionals.","Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi","Zhu, G D","Cao, J","32185921"],"abstract":["Since the end of 2019, the coronavirus disease 2019 (COVID-19) has been extensively epidemic in China, which not only seriously threatens the safety and health of Chinese people, but also challenges the management of other infectious diseases. Currently, there are still approximately three thousand malaria cases imported into China every year. If the diagnosis and treatment of malaria cases as well as the investigation and response of the epidemic foci are not carried out timely, it may endanger patients'lives and cause the possible of secondary transmission, which threatens the achievements of malaria elimination in China. Due to the extensive spread and high transmission ability of the COVID-19, there is a possibility of virus infections among malaria cases during the medical care-seeking behaviors and among healthcare professionals during clinical diagnosis and treatment, sample collection and testing and epidemiological surveys. This paper analyzes the challenges of the COVID-19 for Chinese malaria elimination programme, and proposes the countermeasures in response to the COVID-19 outbreak, so as to provide the reference for healthcare professionals."],"journal":"Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi","authors":["Zhu, G D","Cao, J"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32185921","week":"202012|Mar 16 - Mar 22","doi":"10.16250/j.32.1374.2020036","keywords":["challenge","coronavirus disease 2019 (covid-19)","countermeasure","elimination","malaria"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China","Chinese","China","China","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874554851328,"score":241.33038},{"pmid":32162896,"title":"Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.","text":["Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.","The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an alpha-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19.","Minerva Gastroenterol Dietol","Di Pierro, Francesco","Bertuccioli, Alexander","Cavecchia, Ilaria","32162896"],"abstract":["The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an alpha-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19."],"journal":"Minerva Gastroenterol Dietol","authors":["Di Pierro, Francesco","Bertuccioli, Alexander","Cavecchia, Ilaria"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162896","week":"202011|Mar 09 - Mar 15","doi":"10.23736/S1121-421X.20.02697-5","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["avian"],"_version_":1664640874774003713,"score":196.8254},{"pmid":32253172,"title":"Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?","text":["Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?","Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), has posed a serious threat to global health and is currently causing a major pandemic. While patients typically present with fever and a respiratory illness, mounting evidence indicates that patients might also report extra-pulmonary manifestations, including those affecting the liver and gastrointestinal tract. This involvement may have important implications to the disease management, transmission, and prognosis, especially in patients with pre-existing hepatic or digestive co-morbidities. In this review, the characteristics and possible explanations of hepatic and gastrointestinal involvement caused by SARS-CoV-2 infection are summarized, adding to our knowledge of the spectrum of COVID-19. In addition, preventive measures implemented in endoscopy departments to prevent further dissemination of SARS-CoV-2 infection are proposed.","Arab J Gastroenterol","Musa, Sherief","32253172"],"abstract":["Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), has posed a serious threat to global health and is currently causing a major pandemic. While patients typically present with fever and a respiratory illness, mounting evidence indicates that patients might also report extra-pulmonary manifestations, including those affecting the liver and gastrointestinal tract. This involvement may have important implications to the disease management, transmission, and prognosis, especially in patients with pre-existing hepatic or digestive co-morbidities. In this review, the characteristics and possible explanations of hepatic and gastrointestinal involvement caused by SARS-CoV-2 infection are summarized, adding to our knowledge of the spectrum of COVID-19. In addition, preventive measures implemented in endoscopy departments to prevent further dissemination of SARS-CoV-2 infection are proposed."],"journal":"Arab J Gastroenterol","authors":["Musa, Sherief"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253172","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ajg.2020.03.002","keywords":["covid-19","endoscopy","gastrointestinal tract","liver","sars-cov-2"],"source":"PubMed","topics":["Prevention","Diagnosis","Mechanism"],"weight":1,"_version_":1664640769722417152,"score":155.71584},{"pmid":32266987,"title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).","text":["Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).","OBJECTIVES: To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). DESIGN, SETTING: Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020. PARTICIPANTS: Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals. MAIN OUTCOME MEASURES: Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy). RESULTS: Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days). CONCLUSIONS: Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated.","Med J Aust","Zha, Lei","Li, Shirong","Pan, Lingling","Tefsen, Boris","Li, Yeshan","French, Neil","Chen, Liyun","Yang, Gang","Villanueva, Elmer V","32266987"],"abstract":["OBJECTIVES: To assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). DESIGN, SETTING: Observational study in the two COVID-19-designated hospitals in Wuhu, Anhui province, China, 24 January - 24 February 2020. PARTICIPANTS: Thirty-one patients infected with the severe acute respiratory coronavirus 2 (SARS-CoV-2) treated at the two designated hospitals. MAIN OUTCOME MEASURES: Virus clearance time, length of hospital stay, and duration of symptoms, by treatment type (including or not including corticosteroid therapy). RESULTS: Eleven of 31 patients with COVID-19 received corticosteroid treatment. Cox proportional hazards regression analysis indicated no association between corticosteroid treatment and virus clearance time (hazard ratio [HR], 1.26; 95% CI, 0.58-2.74), hospital length of stay (HR, 0.77; 95% CI, 0.33-1.78), or duration of symptoms (HR, 0.86; 95% CI, 0.40-1.83). Univariate analysis indicated that virus clearance was slower in two patients with chronic hepatitis B infections (mean difference, 10.6 days; 95% CI, 6.2-15.1 days). CONCLUSIONS: Corticosteroids are widely used when treating patients with COVID-19, but we found no association between therapy and outcomes in patients without acute respiratory distress syndrome. An existing HBV infection may delay SARS-CoV-2 clearance, and this association should be further investigated."],"journal":"Med J Aust","authors":["Zha, Lei","Li, Shirong","Pan, Lingling","Tefsen, Boris","Li, Yeshan","French, Neil","Chen, Liyun","Yang, Gang","Villanueva, Elmer V"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266987","week":"202015|Apr 06 - Apr 12","doi":"10.5694/mja2.50577","keywords":["corticosteroids","epidemics","pneumonia, viral"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhu","Anhui","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637635992223744,"score":144.50015},{"pmid":32327306,"title":"New paths for sustainable solutions to tackle global and emerging infectious threats.","text":["New paths for sustainable solutions to tackle global and emerging infectious threats.","With the dramatic background of a newly emerged virus (SARS-CoV-2) spreading around the world, Coronavirus and other infectious health threats for the human and animal populations were illustrated and debated in excellent presentations at the IABS meeting 26-28 of February 2020. Historical evidence of pandemics and lessons learned from recent epidemics or epizootics caused by many pathogens (e.g., Ebola, Zika, and African Swine Fever viruses) illustrated the overarching need for close international cooperation. New and old technologies in vaccine development and their use were presented, resulting in a call for greater interaction between the human and the veterinary fields in order to leverage the expertise and knowledge in both human and animal medicine. The One Health concept was also emphasized for eliminating the 59,000 fatal human rabies cases annually attributed to unvaccinated dogs. For preventable, infectious diseases commonly spreading in the poorer regions of the world, a new regulatory approach and governance structure was called for to give access to affordable vaccines. Vaccines were touted as one of the most successful health invention ever introduced; on a similar level to health improvements due to clean water.","Biologicals","Holm, Anja","32327306"],"abstract":["With the dramatic background of a newly emerged virus (SARS-CoV-2) spreading around the world, Coronavirus and other infectious health threats for the human and animal populations were illustrated and debated in excellent presentations at the IABS meeting 26-28 of February 2020. Historical evidence of pandemics and lessons learned from recent epidemics or epizootics caused by many pathogens (e.g., Ebola, Zika, and African Swine Fever viruses) illustrated the overarching need for close international cooperation. New and old technologies in vaccine development and their use were presented, resulting in a call for greater interaction between the human and the veterinary fields in order to leverage the expertise and knowledge in both human and animal medicine. The One Health concept was also emphasized for eliminating the 59,000 fatal human rabies cases annually attributed to unvaccinated dogs. For preventable, infectious diseases commonly spreading in the poorer regions of the world, a new regulatory approach and governance structure was called for to give access to affordable vaccines. Vaccines were touted as one of the most successful health invention ever introduced; on a similar level to health improvements due to clean water."],"journal":"Biologicals","authors":["Holm, Anja"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327306","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.biologicals.2020.04.003","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Ebola","Zika"],"e_drugs":["Water"],"_version_":1664996914994610176,"score":143.1758}]}